Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score

Proliferation (Ki-67 and Phosphohistone H3) and Oncotype DX Recurrence Score in Estrogen Receptor-positive Breast Cancer

(2011) Daron J. Williams et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

A Lower Allred Score for Progesterone Receptor Is Strongly Associated With a Higher Recurrence Score of 21-Gene Assay in Breast Cancer

(2010) Ping Tang et al.   CANCER INVESTIGATION

Ki67 in breast cancer: prognostic and predictive potential

(2010) Rinat Yerushalmi et al.   LANCET ONCOLOGY

Complementary Value of the Ki-67 Proliferation Index to the Oncotype DX Recurrence Score

(2009) Katja Gwin et al.   INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY

Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial

(2009) Judith Hugh et al.   JOURNAL OF CLINICAL ONCOLOGY

Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) Frédérique Penault-Llorca et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis

(2009) Reiki Nishimura et al.   Breast Cancer

Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

(2008) Giuseppe Viale et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer

(2008) Giuseppe Viale et al.   JNCI-Journal of the National Cancer Institute

Histopathologic variables predict Oncotype DX™ Recurrence Score

(2008) Melina B Flanagan et al.   MODERN PATHOLOGY